Ph.D. Professor Tomohiro Terada
Our laboratory aims to contribute to the provision of pharmaceutical care with safety and high quality by 1) promoting individualization and optimization of drug therapy (Drug Fostering and Evolution), 2) identifying the mechanisms and molecules involved in the development of diseases and adverse drug reaction, and to propose new therapeutic and preventive drugs (Drug development), and 3) disseminating new evidence on pharmacist services. To this end, we are promoting so-called "Reverse Translational Research" (Fig. 1). We are convinced that the logical thinking and sense acquired through research will enable us to break new ground as clinical pharmacists.
Research and Education
[Research] We are promoting the following clinical problem-solving research (Fig. 2).
- Establishment of individualized pharmacotherapy for high-alert medication such as immunosuppressive drugs
- Research on effectiveness and safety of drugs based on data science
- Development of novel drug therapies for intractable diseases
- Pharmaceutical research on inhalation drug delivery
- Reverse translational research aiming for prevention and treatment of adverse drug events
- Research on the optimal usage of pharmaceuticals and evaluation of pharmacist practices
We are conducting clinical research using medical record databases and devising patient-specific dosage design methods based on pharmacokinetic models.
[Education] The graduate students of the Graduate School of Medicine and Graduate School of Pharmaceutical Sciences are enrolled in our laboratory. They are working on the above issues in collaboration with the doctors and pharmacists. In addition, pharmacists who wish to solve clinical problems also conduct research under the guidance of faculty members. We are looking forward to those who want to pursue the science of “Pharmacotherapy” and create new evidence for pharmacists’ work.
Figure 1. Research overview
Figure 2. Translational and reverse translational research in our laboratory
Recent Publications
- Kawata M., Yonezawa A., Mineharu Y., Itohara K., Mizota T., Matsui Y., Kikuchi T., Yamao Y., Hattori E. Y., Hamada M., Hira D., Furukawa K., Miyamoto S., Terada T., Matsubara K. & Arakawa Y. Development of extended pharmacokinetic models for propofol based on measured blood and brain concentrations. Sci Rep 14, 6326, (2024).
- Yamashita Y, Hira D, Morita M, Katsube Y, Takakura M, Tomotaki H, Tomotaki S, Xiong W, Shiomi H, Horie T, Ueshima S, Mizuno T, Terada T, Ono K. Potential treatment option of rivaroxaban for breastfeeding women: A case series. Thromb Res 237, 141–144, (2024).
- Katada Y., Nakagawa S., Nagao M., Umemura K., Itohara K., Nishikawa A., Hashi S., Katsube Y., Hira D., Ohsumi A., Nakajima D., Date H. & Terada T. Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis. Transpl Infect Dis, 25, e14141, (2023).
- Sukeishi A., Itohara K., Yonezawa A., Sato Y., Matsumura K., Katada Y., Nakagawa T., Hamada S., Tanabe N., Imoto E., Kai S., Hirai T., Yanagita M., Ohtsuru S., Terada T. & Ito I. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction. CPT Pharmacometrics Syst Pharmacol 11, 94-103, (2022).
- Ikuta K, Nakagawa S, Momo K, Yonezawa A, Itohara K, Sato Y, Imai S, Nakagawa T, Matsubara K: Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study. BMJ Open, 11: e041543 (2021)
Laboratory
Professor: Tomohiro Terada, Ph.D.
Associate Professor: Shunsaku Nakagawa, Ph.D.
Senior Lecturer: Daiki Hira, Ph.D.
Assistant Professor: Yuki Shigetsura, Ph.D., Natsuki Imayoshi, Ph.D.
Assistant Professor (Program-Specific): Yurie Katsube, Ph.D., Keiko Ikuta, Ph.D., Yuki Kunitsu, Ph.D.
TEL：+81-75-751-3577
FAX：+81-75-751-4207
e-mail：teradat@kuhp.kyoto-u.ac.jp
URL:http://www.kuhp.kyoto-u.ac.jp/~yakuzai/english/index.html